25 related articles for article (PubMed ID: 38462034)
1. Myotubularin related protein 7 is essential for the spermatogonial stem cell homeostasis via PI3K/AKT signaling.
Zhao D; Shen C; Gao T; Li H; Guo Y; Li F; Liu C; Liu Y; Chen X; Zhang X; Wu Y; Yu Y; Lin M; Yuan Y; Chen X; Huang X; Yang S; Yu J; Zhang J; Zheng B
Cell Cycle; 2019 Oct; 18(20):2800-2813. PubMed ID: 31478454
[TBL] [Abstract][Full Text] [Related]
2. Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer.
Weidner P; Söhn M; Gutting T; Friedrich T; Gaiser T; Magdeburg J; Kienle P; Ruh H; Hopf C; Behrens HM; Röcken C; Hanoch T; Seger R; Ebert MP; Burgermeister E
Oncotarget; 2016 Aug; 7(31):50490-50506. PubMed ID: 27409167
[TBL] [Abstract][Full Text] [Related]
3. Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma.
Weidner P; Söhn M; Schroeder T; Helm L; Hauber V; Gutting T; Betge J; Röcken C; Rohrbacher FN; Pattabiraman VR; Bode JW; Seger R; Saar D; Nunes-Alves A; Wade RC; Ebert MPA; Burgermeister E
Oncogenesis; 2020 Jun; 9(6):59. PubMed ID: 32522977
[TBL] [Abstract][Full Text] [Related]
4. Characterization of myotubularin-related protein 7 and its binding partner, myotubularin-related protein 9.
Mochizuki Y; Majerus PW
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9768-73. PubMed ID: 12890864
[TBL] [Abstract][Full Text] [Related]
5. Silencing myotubularin related protein 7 enhances proliferation and early differentiation of C2C12 myoblast.
Yuan Z; Chen Y; Zhang X; Zhou X; Li M; Chen H; Wu M; Zhang Y; Mo D
Biochem Biophys Res Commun; 2017 Mar; 484(3):592-597. PubMed ID: 28153733
[TBL] [Abstract][Full Text] [Related]
6. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
[TBL] [Abstract][Full Text] [Related]
7. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract][Full Text] [Related]
9. RAS GTPase signalling to alternative effector pathways.
Singh S; Smith MJ
Biochem Soc Trans; 2020 Oct; 48(5):2241-2252. PubMed ID: 33125484
[TBL] [Abstract][Full Text] [Related]
10. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
11. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Fang B
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
[TBL] [Abstract][Full Text] [Related]
12. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.
Kidger AM; Sipthorp J; Cook SJ
Pharmacol Ther; 2018 Jul; 187():45-60. PubMed ID: 29454854
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
